Traxens Announces Partnership With COSCO
1.9.2020 09:30:00 EEST | Business Wire | Press release
Traxens, a company that provides high-value data and services for the supply chain industry, announces today a major partnership with COSCO Shipping Logistics that aims to promote a full set of IoT data services based on Traxens cutting-edge smart container solutions. Both companies are carrying out a test program to provide IoT data services to COSCO Shipping Logistics’ large worldwide base of beneficial cargo owners (BCO) customers and aiming to join force in promoting supply chain digitalization. This follows the opening of Traxens’ China office – its first outside of France.
COSCO is a leading global shipping company and a container logistics operator in China. In partnering with COSCO, Traxens will be able to demonstrate its capacity in creating customer values through promoting its smart container solutions and digital services, and significantly contributing to the ongoing digitalization of the global container logistics industry. As the global supply chain becomes more and more competitive, improved tracking and smart data management is an increasingly important differentiation factor for all the major players in the shipping industry.
Through this partnership, COSCO will be able to offer premium data services to its large base of BCOs who are seeking door-to-door visibility and ever-increasing efficiency in their supply chains. This joint development in container supply chain digitalization marks a milestone in Traxens’ international expansion strategy and will help the company push forward with further business development in Asia.
“Our main focus as a business is to be able to create substantial customer value by delivering superior solution and services through technological innovation and global customer support capacity” said David Marchand, Traxens CEO. “Our partnership with COSCO will greatly benefit cargo owners and end-users and encourage further digitalization of the container logistics industry to the benefit of customers worldwide.”
“Traxens is delighted to be working with COSCO, providing its industry-proven smart container solutions to help streamline the company’s operations and enhance customers experience,” said Vincent Gu, managing director, Traxens Asia-Pacific. “Providing fleets with global visibility, exception management and business intelligence is what Traxens does best. By partnering up with global shipping companies such as COSCO we are able to demonstrate what our market-leading IoT solutions are capable of, giving client companies end-to-end shipment visibility and predictive insights that will benefit the end-users and the whole industry.”
“Through our partnership with Traxens, we aim to be at the forefront of digitalization and to maintain our leadership in the global container logistics industry ” said Sheng Liu, general manager of the container logistics division of COSCO SHIPPING Logistics. “As a leading global logistics company, we always pay close attention to the needs of our customers in their supply chain. We believe that the IoT services developed by Traxens are important to improve tracking and management of moving assets.”
About COSCO Shipping
COSCO SHIPPING Logistics Co., Ltd (COSCO SHIPPING Logistics), affiliated to CHINA COSCO SHIPPING CORPORATION LIMITED, is an international integrated logistics enterprise with shipping logistics as its core. It can provide modernized and professional whole-process logistics and supply chain solutions for customers at home and abroad. With a strong reputation and professional service capabilities, it is an important partner for governments, ports, railways, airports and large multinational companies.
The company, with headquarters in Beijing, is merged with CHINA COSCO Logistics Co., Ltd.(a part of COSCO Group), China Shipping Logistics Co., Ltd. (China Shipping Group) and China Shipping Agency Co., Ltd. (China Shipping Group). It was launched on December 21, 2016. China Ocean Shipping Tally Company was incorporated into COSCO SHIPPING Logistics after integration on September 18, 2017.
The company’s service network covers 30 provinces in China and many other countries and regions in Europe, America, Asia and Africa. There are over 600 sales and service points throughout the world; such broad sales and service networks provide customers with a full range of logistics solutions. Since its establishment, COSCO Shipping Logistics has won the Golden Pegasus Prize and has for many years been recognised as one of the National Advanced Logistics Enterprises.
http://www.cosco-logistics.com.cn/
About Traxens
Traxens drives digital transformation in the global supply chain. The company’s breakthrough IoT technology, data science expertise, global logistics experience and standards leadership unlock the value of real-time data generated from cargo assets shipped by sea, rail and road. Traxens is trusted by hundreds of global cargo owners, enabling them to reduce door-to-door transport costs, optimize their investments and minimize risk. By partnering with the world’s leading shipping lines, rail carriers and smart ports, Traxens helps all members of the global supply chain ecosystem improve decision making, operations and customer service. Traxens is privately held and headquartered in Marseille, France.
www.traxens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005361/en/
Contact information
Géraldine Saunière
Director of Communications
Mail: g.sauniere@traxens.com
Tel: +33-695-915-899
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom